Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Avastin | Bevacizumab | Withdrawn | ||||
| Avastin | Bevacizumab | Cervical Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn | |||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
| Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 6, 2024